The inhibition of glycogen synthase kinase 3β (GSK3β) activity through pharmacological intervention represents a promising approach for treating challenging neurodegenerative disorders like Alzheimer’s disease. Here, GSK3B is linked to early-onset autosomal dominant Alzheimer disease.